Chemistry:RTI-83
Clinical data | |
---|---|
Other names | RTI-4229-83 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H25NO2 |
Molar mass | 287.403 g·mol−1 |
3D model (JSmol) | |
| |
|
RTI-83 ((–)-2β-carbomethoxy-3β-(4-ethylphenyl)tropane) is a phenyltropane derivative which represents a rare example of an SDRI or serotonin-dopamine reuptake inhibitor, a drug which inhibits the reuptake of the neurotransmitters serotonin and dopamine, while having little or no effect on the reuptake of the related neurotransmitter noradrenaline. With a binding affinity (Ki) of 55 nM at DAT and 28.4 nM at SERT but only 4030 nM at NET, RTI-83 has reasonable selectivity for DAT/SERT over NET
However, further research has shown that by extending the ethyl chain even better selectivity can be achieved, with the 4′-(cis-propenyl) analogue having Ki values of 15 nM at DAT and 7.1 nM at SERT, vs 2800 nM at NET.[1][2] However RTI-436 has an even better selectivity for DAT over NET (3.09 nM @ DAT and 1,960 nM @ NET, or a NET/DAT ratio of 634.3, but with lesser DAT/SERT equivalent potency with a ratio between them of 108) and RTI-88 has a still better ratio (984 NET/DAT with additionally having less selectivity than the former compound between DAT/SERT and having a more even spread of potency with the ratio between DAT and SERT being 88).
Compound | DAT
[3H]WIN-35428 |
5-HTT
[3H]Paroxetine |
NET
[3H]Nisoxetine |
Selectivity
5-HTT/DAT |
Selectivity
NET/DAT | |||
---|---|---|---|---|---|---|---|---|
RTI-83 | 55 ± 2.1 | 28.4 ± 3.8 | 4,030 ± 381 | 0.5 | 73.3 | |||
RTI-102 | 474 | 1928 | 43,400 | 4.06 | 91.5 | |||
RTI-304 | 15 ± 1.2 | 7.1 ± 0.71 | 2,800 ± 300 | 0.5 | 186.6 | |||
RTI-88 | 1.35 ± 0.11 | 120 ± 4 | 1,329 ± 124 | 88.9 | 984.0 | |||
83a* ‡ | 1.20 ± 0.29 | 48.7 ± 8.4 | 10,000.0 | 40.6 | 8,333.3 | |||
RTI-143 | 4.06 ± 0.22 | 404 ± 56 | 40,270 ± 180 | 99.5 | 9,919.0 | |||
*C3β-Ph-para=iodo, C2β-R=CO2-i-Pr, N8=CH2CH2CH2F ‡Compound code for phenyltropane in accord with Singh's "Chemistry, Design & SAR of cocaine antagonists" paper nomenclature, of no relation to RTI naming convention despite similarity to namesake of drug on topic.[3] |
Such drugs are speculated to be useful as potential antidepressants, but few examples have been reported in the literature as yet. However, while RTI-83 has been used for binding studies to model the monoamine transporter proteins,[4] its pharmacology in vivo has not been studied in detail.
See also
References
- ↑ "Synthesis and transporter binding properties of 3 beta-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2 beta-carboxylic acid methyl esters: serotonin transporter selective analogs". Journal of Medicinal Chemistry 39 (20): 4027–35. September 1996. doi:10.1021/jm960409s. PMID 8831768.
- ↑ "Chemistry, design, and structure-activity relationship of cocaine antagonists". Chemical Reviews 100 (3): 925–1024. March 2000. doi:10.1021/cr9700538. PMID 11749256.
- ↑ Singh, Satendra (2010). "Chem Inform Abstract: Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists". ChemInform 31 (20): no. doi:10.1002/chin.200020238.
- ↑ "Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters". The Journal of Pharmacology and Experimental Therapeutics 308 (2): 679–87. February 2004. doi:10.1124/jpet.103.057836. PMID 14593087.
External links
- "Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter". Journal of Medicinal Chemistry 51 (24): 8048–56. December 2008. doi:10.1021/jm801162z. PMID 19053748.
Original source: https://en.wikipedia.org/wiki/RTI-83.
Read more |